Uniqure Nv Share Price (NASDAQ: QURE)

$16.23

▲

0.48

(3.05%)

Live

Last updated on August 29, 2025 at 1:29 am IST

$₹

Check the interactive Uniqure Nv Stock chart to analyse performance

Uniqure Nv stock performance

as on August 29, 2025 at 1:29 am IST

Today's Low:$15.85
Today's High:$16.63
$16.23
2.37%
Downside
Day's Volatility :4.72%
Upside
2.41%
52 Weeks Low:$4.45
52 Weeks High:$19.18
$16.23
72.58%
Downside
52 Weeks Volatility :76.8%
Upside
15.38%

Uniqure Nv Stock Returns

Period	Uniqure Nv	Sector (Health Care)	Index (Russel 2000)
3 Months	5.7%	4.2%	0.0%
6 Months	30.49%	-8.0%	0.0%
1 Year	159.69%	-12.1%	0.0%
3 Years	-19.56%	7.6%	-6.9%

Uniqure Nv Key Stats

Check Uniqure Nv key stats like market cap, P/E ratio, EPS, Dividend Yield, and more.

Previous Close	$15.75
Open	$15.88
Today's High	$16.63
Today's Low	$15.845
Market Capitalization	$866.3M
Today's Volume	$617.5K
52 Week High	$19.18
52 Week Low	$4.45
Revenue TTM	$14.3M
EBITDA	$-146.4M
Earnings Per Share (EPS)	$-3.9
Profit Margin	0.0%
Quarterly Earnings Growth YOY	-0.18%
Return On Equity TTM	-427.47%

Stock Returns calculator for Uniqure Nv Stock including INR - Dollar returns

The Uniqure Nv stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

Uniqure Nv investment value today

Current value as on today

₹2,65,363

Returns

₹1,65,363

(+165.36%)

Returns from Uniqure Nv Stock

₹1,60,932 (+160.93%)

Dollar Returns*

₹4,430 (+4.43%)

Indian investors sentiment towards Uniqure Nv Stock

-81%

Period: Jul 29, 2025 to Aug 28, 2025. Change in 30 Days versus previous period

Search interest for Uniqure Nv Stock from India on INDmoney has decreased by -81% in the last 30 days, reflecting a downward trend in search activity.

Global Institutional Holdings in Uniqure Nv

Name
Holdings %
Name
Holdings %
RTW INVESTMENTS, LLC
9.40%
Vestal Point Capital LP
8.73%
EcoR1 Capital, LLC
7.27%
venBio Select Advisor LLC
6.61%
Aberdeen Group PLC
5.01%
Nantahala Capital Management, LLC
3.74%

Analyst Recommendation on Uniqure Nv Stock

Rating

Trend

Buy

75%Buy

25%Hold

0%Sell

Based on 20 Wall street analysts offering stock ratings for Uniqure Nv(by analysts ranked 0 to 5 stars)

Uniqure Nv Share Price Target

What analysts predicted

Upside of 128.2%

Target:

$37.04

Current:

$16.23

Uniqure Nv share price target is $37.04, a slight Upside of 128.2% compared to current price of $16.23 as per analysts' prediction.

Uniqure Nv Stock Insights

Price Movement
In the last 1 year, QURE stock has moved up by 159.7%
Increasing Revenue
Revenue is up for the last 2 quarters, 1.56M → 5.26M (in $), with an average increase of 70.2% per quarter
Increasing Net Profit
Netprofit is up for the last 3 quarters, -73.26M → -37.71M (in $), with an average increase of 41.8% per quarter
QURE vs ALNY (3 yr)
In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 115.3% return, outperforming this stock by 135.9%

Uniqure Nv Financials

Revenue

Profit

Cash Flow

Annually

Quarterly

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Revenue	$7.3M	↓ 35.48%
Net Income	$-124.2M	↑ 49.09%
Net Profit Margin	-1.7K%	↓ 967.57%

	FY20	Y/Y Change
Revenue	$37.5M	↑ 415.23%
Net Income	$-125.0M	↑ 0.66%
Net Profit Margin	-333.27%	↑ 1372.55%

	FY21	Y/Y Change
Revenue	$524.0M	↑ 1296.82%
Net Income	$329.6M	↓ 363.62%
Net Profit Margin	62.9%	↑ 396.17%

	FY22	Y/Y Change
Revenue	$106.5M	↓ 79.68%
Net Income	$-126.8M	↓ 138.47%
Net Profit Margin	-119.07%	↓ 181.97%

	FY23	Y/Y Change
Revenue	$15.8M	↓ 85.12%
Net Income	$-308.5M	↑ 143.3%
Net Profit Margin	-1.9K%	↓ 1828.02%

	FY24	Y/Y Change
Revenue	$27.1M	↑ 71.17%
Net Income	$-239.6M	↓ 22.34%
Net Profit Margin	-883.35%	↑ 1063.74%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Revenue	$8.5M	↑ 26.85%
Net Income	$-65.6M	↓ 10.37%
Net Profit Margin	-773.34%	↑ 321.08%

	Q2 FY24	Q/Q Change
Revenue	$11.1M	↑ 31.13%
Net Income	$-56.3M	↓ 14.2%
Net Profit Margin	-506.01%	↑ 267.33%

	Q3 FY24	Q/Q Change
Revenue	$2.3M	↓ 79.44%
Net Income	$-44.4M	↓ 21.17%
Net Profit Margin	-1.9K%	↓ 1434.44%

	Q4 FY24	Q/Q Change
Revenue	$5.2M	↑ 128.29%
Net Income	$-73.3M	↑ 65.08%
Net Profit Margin	-1.4K%	↑ 537.25%

	Q1 FY25	Q/Q Change
Revenue	$1.6M	↓ 69.99%
Net Income	$-43.6M	↓ 40.44%
Net Profit Margin	-2.8K%	↓ 1381.55%

	Q2 FY25	Q/Q Change
Revenue	$5.3M	↑ 235.8%
Net Income	$-37.7M	↓ 13.56%
Net Profit Margin	-716.82%	↑ 2067.93%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Profit	$-87.5M	↑ 41.57%

	FY20	Y/Y Change
Profit	$-84.9M	↓ 2.94%

	FY21	Y/Y Change
Profit	$499.0M	↓ 687.88%

	FY22	Y/Y Change
Profit	$103.1M	↓ 79.33%

	FY23	Y/Y Change
Profit	$2.2M	↓ 97.85%

	FY24	Y/Y Change
Profit	$8.8M	↑ 296.93%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Profit	$-3.4M	↑ 57.04%

	Q2 FY24	Q/Q Change
Profit	$995.0K	↓ 129.53%

	Q3 FY24	Q/Q Change
Profit	$1.3M	↑ 27.24%

	Q4 FY24	Q/Q Change
Profit	$4.6M	↑ 263.51%

	Q1 FY25	Q/Q Change
Profit	$1.4M	↓ 70.23%

	Q2 FY25	Q/Q Change
Profit	$4.6M	↑ 236.2%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Operating Cash Flow	$-98.7M	↑ 29.78%
Investing Cash Flow	$-6.6M	↑ 56.58%
Financing Cash Flow	$248.8M	↑ 57.52%

	FY20	Y/Y Change
Operating Cash Flow	$-134.8M	↑ 36.63%
Investing Cash Flow	$-9.5M	↑ 42.68%
Financing Cash Flow	$7.4M	↓ 97.01%

	FY21	Y/Y Change
Operating Cash Flow	$288.0M	↓ 313.58%
Investing Cash Flow	$-67.4M	↑ 610.53%
Financing Cash Flow	$94.9M	↑ 1174.29%

	FY22	Y/Y Change
Operating Cash Flow	$-145.1M	↓ 150.38%
Investing Cash Flow	$-182.7M	↑ 171.17%
Financing Cash Flow	$1.4M	↓ 98.48%

	FY23	Y/Y Change
Operating Cash Flow	$-145.9M	↑ 0.6%
Investing Cash Flow	$-205.7M	↑ 12.56%
Financing Cash Flow	$362.7M	↑ 25001.8%

	FY24	Y/Y Change
Operating Cash Flow	$-182.7M	↑ 25.22%
Investing Cash Flow	$163.0M	↓ 179.23%
Financing Cash Flow	$-59.5M	↓ 116.4%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Operating Cash Flow	$-60.6M	↑ 22.27%
Investing Cash Flow	$64.0M	↑ 7.43%
Financing Cash Flow	$0.0	↓ 100.0%

	Q2 FY24	Q/Q Change
Operating Cash Flow	$-32.7M	↓ 46.0%
Investing Cash Flow	$77.9M	↑ 21.81%
Financing Cash Flow	$49.8K	-

	Q3 FY24	Q/Q Change
Operating Cash Flow	$-36.6M	↑ 11.88%
Investing Cash Flow	$47.7M	↓ 38.84%
Financing Cash Flow	$-53.0M	↓ 106563.45%

	Q4 FY24	Q/Q Change
Operating Cash Flow	$-52.8M	↑ 44.39%
Investing Cash Flow	$-26.6M	↓ 155.85%
Financing Cash Flow	$-6.5M	↓ 87.71%

	Q1 FY25	Q/Q Change
Operating Cash Flow	$-44.1M	↓ 16.55%
Investing Cash Flow	$20.1M	↓ 175.49%
Financing Cash Flow	$80.7M	↓ 1337.84%

	Q2 FY25	Q/Q Change
Operating Cash Flow	$-39.9M	↓ 9.54%
Investing Cash Flow	$73.1M	↑ 263.57%
Financing Cash Flow	$44.0K	↓ 99.95%

Uniqure Nv Technicals Summary

Sell

Neutral

Buy

Uniqure Nv is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Uniqure Nv Vs Peers

Returns

Ratio's

Overview

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Uniqure Nv	15.13%	30.49%	159.69%	-19.56%	-61.37%
Regeneron Pharmaceuticals, Inc.	5.16%	-16.48%	-51.06%	-0.98%	-5.32%
Beone Medicines Ltd	-1.83%	7.82%	51.46%	79.4%	24.25%
Vertex Pharmaceuticals Incorporated	-16.94%	-18.0%	-20.55%	38.17%	39.4%
Alnylam Pharmaceuticals, Inc.	37.4%	91.56%	61.8%	117.28%	242.42%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Uniqure Nv	2.64	NA	0.0	-2.72	-4.27	-0.15	NA	-0.07
Regeneron Pharmaceuticals, Inc.	14.86	14.86	1.21	39.42	0.15	0.07	0.0	287.55
Beone Medicines Ltd	NA	NA	NA	2.73	-0.05	-0.01	NA	34.32
Vertex Pharmaceuticals Incorporated	27.58	27.58	0.58	18.06	0.23	0.13	NA	67.02
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	3.92	-2.58	-0.03	NA	1.91

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Uniqure Nv	Buy	$866.3M	-61.37%	2.64	0.0%
Regeneron Pharmaceuticals, Inc.	Buy	$62.5B	-5.32%	14.86	31.37%
Beone Medicines Ltd	NA	$37.7B	24.25%	NA	-3.89%
Vertex Pharmaceuticals Incorporated	Buy	$99.3B	39.4%	27.58	31.86%
Alnylam Pharmaceuticals, Inc.	Buy	$59.1B	242.42%	NA	-12.96%

About Uniqure Nv

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in Phase I/II clinical study for the treatment of Huntington's disease. The company also develops AMT-260, which is in Phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in Phase I/IIa clinical trial to treat superoxide dismutase enzyme-amyotrophic lateral sclerosis; and AMT-191, an investigational gene therapy candidate which is in phase I/IIa clinical trial for the treatment of fabry disease. It has a licensing agreement with Apic Bio to develop, manufacture, and commercialize intrathecally administered investigational gene therapy for ALS caused by mutations in SOD-1; and development and commercial supply agreement with CLS Bhering. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.

Organization	Uniqure Nv
Employees	209
CEO	Mr. Matthew Craig Kapusta CPA
Industry	Health Technology

Key Management of Uniqure Nv

Name	Title
Mr. Matthew Craig Kapusta CPA	CEO & Executive Director
Mr. Christian Klemt	CFO, Principal Financial Officer & GM of Amsterdam Site
Dr. Jeannette Potts J.D., Ph.D.	Chief Legal & Compliance Officer and Corporate Secretary
Dr. Walid Abi-Saab M.D.	Chief Medical Officer
Prof. Hugo Katus	Chairman of Scientific Advisory Board and Managing Director of UniQure-Germany
Dr. Amin Abujoub Ph.D.	Chief Technical Operations Officer
Mr. Richard Porter Ph.D.	Chief Business & Scientific Officer
Dr. Tamara Tugal Ph.D., MBA	Business Development Director
Ms. Erin Boyer	Chief People & Culture Officer
Ms. Kylie O'Keefe	Chief Customer & Strategy Officer

Important FAQs about investing in QURE Stock from India :

What is Uniqure Nv share price today?

Uniqure Nv share price today is $16.23 as on August 29, 2025 at 1:29 am IST. Uniqure Nv share today touched a day high of $16.63 and a low of $15.85.

What is the 52 week high and 52 week low for Uniqure Nv share?

Uniqure Nv share touched a 52 week high of $19.18 and a 52 week low of $4.45. Uniqure Nv stock price today i.e. August 29, 2025 at 1:29 am IST is trending at $16.23, lower by 15.38% versus the 52 week high.

How to invest in Uniqure Nv Stock (QURE) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Uniqure Nv on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Uniqure Nv Shares that will get you 0.0924 shares as per Uniqure Nv share price of $16.23 per share as on August 29, 2025 at 1:29 am IST.

What is the minimum amount required to buy Uniqure Nv Stock (QURE) from India?

Indian investors can start investing in Uniqure Nv (QURE) shares with as little as ₹87.6463 or $1 (as of August 29, 2025) using the INDmoney app.
For example: If you want to invest $10 or ₹876.46 in Uniqure Nv stock (as per the Rupee-Dollar exchange rate as on August 29, 2025). Based on Uniqure Nv share’s latest price of $16.23 as on August 29, 2025 at 1:29 am IST, you will get 0.6161 shares of Uniqure Nv. Learn more about fractional shares .

What are the returns that Uniqure Nv has given to Indian investors in the last 5 years?

Uniqure Nv stock has given -61.37% share price returns and 18.6% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?